Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer By Ogkologos - May 18, 2026 44 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Cancer in My Community: Addressing Regional Cancer Disparities in Peru August 24, 2023 “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Load more HOT NEWS Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in... Managing Side Effects with South Asian Foods Dealing With Fears Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk
